You are here: Industry Insights > Market News > AztraZeneca to launch oncology drug Calquence in India

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

AztraZeneca to launch oncology drug Calquence in India

expresspharmaOctober 19, 2020

Tag: AztraZeneca , Acalabrutinib 100 mg capsules , Calquence , oncology drug

Favorites

AstraZeneca Pharma India has received import and market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100 mg capsules (Calquence ). AstraZeneca Pharma India intends to launch Calquence in India on October 21, 2020.

Acalabrutinib 100 mg capsules (Calquence ) is:

Indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).

Previous:Vaccine trials outside home market will help Chinese firms capture Asia, South and Central America markets: GlobalData

Next:US FDA approves Amantadine Hydrochloride Tablets, 100 mg from Alembic Pharma

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

PharmaSourcesJune 14, 2024

Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

PharmaSourcesJune 11, 2024

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress

PharmaSourcesJune 05, 2024

AztraZeneca to launch oncology drug Calquence in India | Pharmasources.com

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs

PharmaSourcesJune 05, 2024

New research showes that biotechs can save more than 30% in costs, halve start-up times, and cut risk with CROs that have in-house scientific and regulatory affairs.

AztraZeneca to launch oncology drug Calquence in India

Related News

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs

You may like